United States Breast Cancer Diagnostic Devices Market Opportunities, 2010 - 2020
As per the statistics furnished by the BreastCancer.org, one in every eight women in the US is anticipated to develop breast cancer over the course of her lifetime. In 2015, an estimated 231,840 new cases of invasive breast cancer and 60,290 new cases of non-invasive breast cancer have been diagnosed in the US. With rising prevalence rate and growing awareness regarding breast cancer, demand for screening and diagnosis is increasing at a robust pace in the United States.
“United States Breast Cancer Diagnostic Devices Market Opportunities, 2010 - 2020” report studies the market size and share of various segments and sub-segments of the breast cancer diagnostic devices market in the United States during the period 2010 - 2020. In the study, the market has been categorized into three broader segments that include Screening and Diagnostic Imaging Devices, Lab Diagnostic Devices and Others.
The market dynamics section of the report elaborates about the factors driving the market as well as the challenges inhibiting growth. The research study also includes insights of the key market trends, a detailed analysis of the changing competitive landscape, and revenue forecasts for each segment and sub-segment.
All this information is provided to assist the established market players and new entrants in taking their strategic decisions, thereby aiding them in strengthening their market position in a highly competitive breast cancer diagnostic devices market in the United States.
“United States Breast Cancer Diagnostic Devices Market Opportunities, 2010 - 2020” report elaborates the following aspects of breast cancer diagnostic devices market in the United States:
The information contained in this report is based upon both primary and secondary sources. Primary research included interviews with breast cancer screening and diagnostic devices manufacturers and industry experts. Secondary research included an exhaustive search of relevant publications like company annual reports, financial reports and other proprietary databases.
“United States Breast Cancer Diagnostic Devices Market Opportunities, 2010 - 2020” report studies the market size and share of various segments and sub-segments of the breast cancer diagnostic devices market in the United States during the period 2010 - 2020. In the study, the market has been categorized into three broader segments that include Screening and Diagnostic Imaging Devices, Lab Diagnostic Devices and Others.
The market dynamics section of the report elaborates about the factors driving the market as well as the challenges inhibiting growth. The research study also includes insights of the key market trends, a detailed analysis of the changing competitive landscape, and revenue forecasts for each segment and sub-segment.
All this information is provided to assist the established market players and new entrants in taking their strategic decisions, thereby aiding them in strengthening their market position in a highly competitive breast cancer diagnostic devices market in the United States.
“United States Breast Cancer Diagnostic Devices Market Opportunities, 2010 - 2020” report elaborates the following aspects of breast cancer diagnostic devices market in the United States:
- United States Breast Cancer Diagnostics Market Size, Share & Forecast
- Segmental Analysis – By Test Type, By Region, By End User, By Company
- Policy & Regulatory Landscape
- Changing Market Trends & Emerging Opportunities
- Competitive Landscape & Strategic Recommendations
- To identify the on-going trends and anticipated growth in the next five years
- To gain competitive knowledge of leading market players
- To avail 10% customization in the report without any extra charges and get the research data or trends added in the report as per the buyer’s specific needs
- What would be the segmental and regional growth trends in the United States breast cancer diagnostic devices market in the coming years?
- What are the most important growth drivers and opportunities in the market?
- Which breast cancer diagnostic procedures is preferred the most?
- What strategies should market competitors employ to gain share in mature segments of the United States breast cancer diagnostic devices market?
- What are the competitor profiles in this market and how do they compete for market share?
The information contained in this report is based upon both primary and secondary sources. Primary research included interviews with breast cancer screening and diagnostic devices manufacturers and industry experts. Secondary research included an exhaustive search of relevant publications like company annual reports, financial reports and other proprietary databases.
1. BREAST CANCER DIAGNOSTIC DEVICES OVERVIEW
2. UNITED STATES BREAST CANCER EPIDEMIOLOGY
3. RESEARCH METHODOLOGY
4. ANALYST VIEW
5. GLOBAL BREAST CANCER DIAGNOSTIC DEVICES MARKET OVERVIEW
6. UNITED STATES BREAST CANCER DIAGNOSTIC DEVICES MARKET OVERVIEW
7. UNITED STATES BREAST CANCER DIAGNOSTIC DEVICES MARKET OUTLOOK
7.1. Market Size and Forecast
7.1.1. By Value
7.2. Market Share and Forecast
7.2.1. By Test Type
7.2.2. By End-user
7.2.3. By Region
7.2.4. By Company
8. UNITED STATES SCREENING AND DIAGNOSTIC IMAGING DEVICES MARKET OUTLOOK
8.1. Market Size and Forecast
8.1.1. By Value
8.2. Market Share and Forecast
8.2.1. By Test Type
8.3. United States Mammography Market Outlook
8.3.1. Market Size and Forecast
8.3.1.1. By Value
8.3.2. Market Share and Forecast
8.3.2.1. By Type (Analog Mammography, 3D Mammography, Full Field Digital Mammography)
9. UNITED STATES LAB DIAGNOSTIC DEVICES MARKET OUTLOOK
9.1. Market Size and Forecast
9.1.1. By Value
9.2. Market Share and Forecast
9.2.1. By Test Type
10. MARKET DYNAMICS
10.1. Drivers
10.2. Challenges
11. MARKET TRENDS & DEVELOPMENTS
11.1. Contrast-enhanced Mammography
11.2. Novel Breast Cancer Diagnostics Biomarkers
11.3. Vacuum-Assisted Biopsy
11.4. CAD for Mammography
11.5. Scintimammography
12. UNITED STATES ECONOMIC PROFILE
13. REGULATORY LANDSCAPE
14. REIMBURSEMENT SCENARIO
15. COMPETITIVE LANDSCAPE
15.1. Competitive Benchmarking
15.2. Company Profiles
15.2.1. Hologic Inc.
15.2.2. Siemens Healthcare Diagnostics, Inc
15.2.3. Devicor Medical Products, Inc. (Mammotome)
15.2.4. GE Healthcare
15.2.5. Philips Healthcare
15.2.6. Carestream Health
15.2.7. Fujifilm Medical Systems, U.S.A., Inc.
15.2.8. IMS S.r.l.
15.2.9. Planmed OY
15.2.10. CareFusion Corporation
16. STRATEGIC RECOMMENDATIONS
2. UNITED STATES BREAST CANCER EPIDEMIOLOGY
3. RESEARCH METHODOLOGY
4. ANALYST VIEW
5. GLOBAL BREAST CANCER DIAGNOSTIC DEVICES MARKET OVERVIEW
6. UNITED STATES BREAST CANCER DIAGNOSTIC DEVICES MARKET OVERVIEW
7. UNITED STATES BREAST CANCER DIAGNOSTIC DEVICES MARKET OUTLOOK
7.1. Market Size and Forecast
7.1.1. By Value
7.2. Market Share and Forecast
7.2.1. By Test Type
7.2.2. By End-user
7.2.3. By Region
7.2.4. By Company
8. UNITED STATES SCREENING AND DIAGNOSTIC IMAGING DEVICES MARKET OUTLOOK
8.1. Market Size and Forecast
8.1.1. By Value
8.2. Market Share and Forecast
8.2.1. By Test Type
8.3. United States Mammography Market Outlook
8.3.1. Market Size and Forecast
8.3.1.1. By Value
8.3.2. Market Share and Forecast
8.3.2.1. By Type (Analog Mammography, 3D Mammography, Full Field Digital Mammography)
9. UNITED STATES LAB DIAGNOSTIC DEVICES MARKET OUTLOOK
9.1. Market Size and Forecast
9.1.1. By Value
9.2. Market Share and Forecast
9.2.1. By Test Type
10. MARKET DYNAMICS
10.1. Drivers
10.2. Challenges
11. MARKET TRENDS & DEVELOPMENTS
11.1. Contrast-enhanced Mammography
11.2. Novel Breast Cancer Diagnostics Biomarkers
11.3. Vacuum-Assisted Biopsy
11.4. CAD for Mammography
11.5. Scintimammography
12. UNITED STATES ECONOMIC PROFILE
13. REGULATORY LANDSCAPE
14. REIMBURSEMENT SCENARIO
15. COMPETITIVE LANDSCAPE
15.1. Competitive Benchmarking
15.2. Company Profiles
15.2.1. Hologic Inc.
15.2.2. Siemens Healthcare Diagnostics, Inc
15.2.3. Devicor Medical Products, Inc. (Mammotome)
15.2.4. GE Healthcare
15.2.5. Philips Healthcare
15.2.6. Carestream Health
15.2.7. Fujifilm Medical Systems, U.S.A., Inc.
15.2.8. IMS S.r.l.
15.2.9. Planmed OY
15.2.10. CareFusion Corporation
16. STRATEGIC RECOMMENDATIONS
LIST OF TABLES
Table 1: Estimated US Breast Cancer Statistics, 2015
Table 2: United States Number of People Aged 65 & Above, 1900 – 2060F
Table 3: Percent of U.S. Women Who Develop Breast Cancer over 10-, 20-, and 30-Year Intervals According to Their Current Age, 2010–2012
Table 4: United States Women Using Mammography (%) within Past Two Years, By age, 1987 - 2013
Table 5: Characteristics Helping Radiologist Differentiate Between Benign and Malignant Tumor
Table 6: Types of Breast Biopsy
Table 7: Lifetime Attributable Risk (LAR) of Breast Cancer Incidence and Mortality per 100,000 Women Undergoing Annual Screening Mammography, By Age (Average Glandular Dose: 3.7 mGy (DM) to 4.7 mGy (SFM) per exam)
Table 8: Major Diagnostic microRNA Signatures for the Early Diagnosis of Breast Cancer
Table 9: Sensitivity of Different Views Based on Lesion Type and Mammography
Table 10: Reimbursement Scenario of Screening and Diagnostic Mammograms and Breast Ultrasound, 2013 & 2014 (USD)
Table 11: New CPT Codes for Percutaneous Breast Procedures, 2014
Table 12: Major Companies Offering Products included in Others Segment
Table 1: Estimated US Breast Cancer Statistics, 2015
Table 2: United States Number of People Aged 65 & Above, 1900 – 2060F
Table 3: Percent of U.S. Women Who Develop Breast Cancer over 10-, 20-, and 30-Year Intervals According to Their Current Age, 2010–2012
Table 4: United States Women Using Mammography (%) within Past Two Years, By age, 1987 - 2013
Table 5: Characteristics Helping Radiologist Differentiate Between Benign and Malignant Tumor
Table 6: Types of Breast Biopsy
Table 7: Lifetime Attributable Risk (LAR) of Breast Cancer Incidence and Mortality per 100,000 Women Undergoing Annual Screening Mammography, By Age (Average Glandular Dose: 3.7 mGy (DM) to 4.7 mGy (SFM) per exam)
Table 8: Major Diagnostic microRNA Signatures for the Early Diagnosis of Breast Cancer
Table 9: Sensitivity of Different Views Based on Lesion Type and Mammography
Table 10: Reimbursement Scenario of Screening and Diagnostic Mammograms and Breast Ultrasound, 2013 & 2014 (USD)
Table 11: New CPT Codes for Percutaneous Breast Procedures, 2014
Table 12: Major Companies Offering Products included in Others Segment
LIST OF FIGURES
Figure 1: United States Breast Cancer Diagnostic Devices Market Size, By Value, 2010-2020F (USD Billion)
Figure 2: United States Breast Cancer Diagnostic Devices Market Share, By Test Type, By Value, 2010-2020F
Figure 3: United States Breast Cancer Diagnostic Devices Market Share, By End User, By Value, 2010-2020F
Figure 4: United States Breast Cancer Diagnostic Devices Market Size, By Region, By Value, 2010-2014 (USD Million)
Figure 5: United States Breast Cancer Diagnostic Devices Market Size, By Region, By Value, 2015-2020 (USD Million)
Figure 6: United States Breast Cancer Diagnostic Devices Market Share, By Region, By Value, 2010-2020F
Figure 7: United States Breast Cancer Diagnostic Devices Market Share, By Company, By Value, 2010-2020F
Figure 8: United States Screening and Diagnostic Imaging Devices Market Size, By Value, 2010-2020F (USD Billion)
Figure 9: United States Breast Cancer Screening and Diagnostic Devices Market Share, By Test Type, By Value, 2010-2020F
Figure 10: United States Mammography Market Size, By Value, 2010-2020F (USD Billion)
Figure 11: United States Mammography Market Share, By Type, By Value, 2010-2020F
Figure 12: Difference between Analog, 2D and 3D Mammography (Same Patient), By Image Quality
Figure 13: United States Lab Diagnostic Devices Market Size, By Value, 2010-2020F (USD Billion)
Figure 14: United States Lab Diagnostic Devices Market Share, By Test Type, By Value, 2010-2020F
Figure 15: Comparison of Standard Mammograph Image and Contrast-enhanced Spectral Mammogram Image
COMPANIES MENTIONED
1. Hologic Inc.
2. Siemens Healthcare Diagnostics, Inc
3. Devicor Medical Products, Inc. (Mammotome)
4. GE Healthcare
5. Philips Healthcare
6. Carestream Health
7. Fujifilm Medical Systems, U.S.A., Inc.
8. IMS S.r.l.
9. Planmed OY
10. CareFusion Corporation
Figure 1: United States Breast Cancer Diagnostic Devices Market Size, By Value, 2010-2020F (USD Billion)
Figure 2: United States Breast Cancer Diagnostic Devices Market Share, By Test Type, By Value, 2010-2020F
Figure 3: United States Breast Cancer Diagnostic Devices Market Share, By End User, By Value, 2010-2020F
Figure 4: United States Breast Cancer Diagnostic Devices Market Size, By Region, By Value, 2010-2014 (USD Million)
Figure 5: United States Breast Cancer Diagnostic Devices Market Size, By Region, By Value, 2015-2020 (USD Million)
Figure 6: United States Breast Cancer Diagnostic Devices Market Share, By Region, By Value, 2010-2020F
Figure 7: United States Breast Cancer Diagnostic Devices Market Share, By Company, By Value, 2010-2020F
Figure 8: United States Screening and Diagnostic Imaging Devices Market Size, By Value, 2010-2020F (USD Billion)
Figure 9: United States Breast Cancer Screening and Diagnostic Devices Market Share, By Test Type, By Value, 2010-2020F
Figure 10: United States Mammography Market Size, By Value, 2010-2020F (USD Billion)
Figure 11: United States Mammography Market Share, By Type, By Value, 2010-2020F
Figure 12: Difference between Analog, 2D and 3D Mammography (Same Patient), By Image Quality
Figure 13: United States Lab Diagnostic Devices Market Size, By Value, 2010-2020F (USD Billion)
Figure 14: United States Lab Diagnostic Devices Market Share, By Test Type, By Value, 2010-2020F
Figure 15: Comparison of Standard Mammograph Image and Contrast-enhanced Spectral Mammogram Image
COMPANIES MENTIONED
1. Hologic Inc.
2. Siemens Healthcare Diagnostics, Inc
3. Devicor Medical Products, Inc. (Mammotome)
4. GE Healthcare
5. Philips Healthcare
6. Carestream Health
7. Fujifilm Medical Systems, U.S.A., Inc.
8. IMS S.r.l.
9. Planmed OY
10. CareFusion Corporation
